Summary & Overview
HCPCS Level II J9302: Injection of ofatumumab, 10 mg
HCPCS Level II code J9302 denotes the administration unit for ofatumumab at 10 mg. Ofatumumab is a monoclonal antibody used in specialty oncology and immunology indications; accurate coding for its administration affects billing, inventory tracking, and payer adjudication nationwide. This code matters for hospitals, infusion centers, and physician practices that deliver biologic injectables.
Key payers in scope include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the payer landscape affecting reimbursement and coverage. The publication outlines common billing modifiers and related administrative considerations, explains service line placement for infusion and injection encounters, and provides benchmark-oriented guidance on where to look for policy updates and reimbursement rules.
The content is intended for national healthcare administrators, revenue cycle managers, and clinicians involved in specialty drug delivery. It highlights what to expect when submitting claims with J9302, where to check payer-specific policies, and the operational implications for infusion services. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J9302 represents an injection of ofatumumab, 10 mg. This code is used to report the administration of the monoclonal antibody formulation at the specified 10 mg unit strength.
Service Type: Injectable biologic administration
Typical Site of Service: Outpatient infusion center or physician office
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with relapsing forms of multiple sclerosis who presents to an outpatient infusion center or hospital outpatient department for treatment with J9302 (ofatumumab). The patient has a neurology follow-up visit documenting disease activity and eligibility for anti-CD20 therapy. Pre-infusion screening includes vitals, recent infection assessment, review of hepatitis B serologies, and medication reconciliation. The patient receives a subcutaneous injection of ofatumumab, with observation for immediate adverse reactions for 30–60 minutes depending on history. Documentation includes indication, dose administered (number of 10 mg units), lot number, route (subcutaneous), administration site, patient tolerance, and any observed reactions. Billing occurs under HCPCS Level II code J9302 per 10 mg increment; contemporaneous CPT services such as evaluation and management, injection administration, or monitoring may be reported per payer policy and documented separately.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered |